Q-omics provides the consensus-scored EIF4A2P5 profile across patient tissues and cancer cell-line models. EIF4A2P5 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, EIF4A2P5 is differentially expressed in 2, with the highest sampling consensus in LUAD. Additionally, EIF4A2P5 RNA expression shows 5,965 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, and STAD as cancer lineages where EIF4A2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4A2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4A2P5 survival associations across molecular data types. EIF4A2P5 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4A2P5 RNA expression–survival associations across cancer types. High EIF4A2P5 expression shows unfavorable associations in LUAD, PCPG, READ, BLCA and HNSC, but favorable associations in ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify LUAD as the clearest survival context for EIF4A2P5 RNA expression.
This table summarizes EIF4A2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4A2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4A2P5 shows higher tumor expression in LUAD and KIRC. The LUAD box plot shows higher EIF4A2P5 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .026).
This table shows molecular features associated with EIF4A2P5 in patient tissues and cancer cell lines. In patient samples, EIF4A2P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
